Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 10/20 | 0.42 |
| ▸ | MAOB | P27338 | 10/20 | 0.42 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 5/20 | 0.39 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3753297 | 0.84 | CYP11B1 (0.58) | CYP11B1CYP11B2MAOAMAOBTRPV4 | |
| SCHEMBL27274265 | 0.83 | MAOB (0.44) | MAOAMAOBTRPV4ARPGR | |
| SCHEMBL12126140 | 0.81 | MAOB (0.57) | CYP11B1CYP11B2MAOAMAOBAR | |
| SCHEMBL6828399 | 0.80 | MAOB (0.42) | MAOAMAOBTRPV4ARPGR | |
| SCHEMBL27274267 | 0.79 | MAOB (0.49) | MAOAMAOBARMAPT | |
| SCHEMBL15973611 | 0.78 | TSHR (0.45) | CYP11B1CYP11B2MAOAMAOBAR | |
| SCHEMBL16555431 | 0.77 | AR (0.41) | MAOAMAOBTRPV4ARPGR | |
| SCHEMBL6831166 | 0.76 | MAPT (0.40) | CYP11B1CYP11B2MAOAMAOBMEN1 | |
| SCHEMBL13946937 | 0.76 | MCL1 (0.47) | CYP11B1CYP11B2MAOAMAOBMEN1 | |
| SCHEMBL15716037 | 0.76 | MAOB (0.46) | CYP11B1CYP11B2MAOAMAOBAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10457707-B2 | Substituted urea depsipeptide analogs as activators of the CLPP endopeptidase | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190048040-A1 | Substituted Urea Depsipeptide Analogs as Activators of the CLPP Endopeptidase | ST JUDE CHILDRENS RES HOSPITAL (US) | 2019-02-14 | — | — | US | disclosed |
| US-20040023938-A1 | Sulfonamide derivatives | TABUCHI TAKANORI (JP) | 2004-02-05 | — | — | US | disclosed |
| US-6586617-B1 | Nontoxic microbiocides such as 4'-chloro-N-ethyl-2'-nitro-p-toluenesulfonanilide, for agricultural or horticultural, prepared by alkylation or nitration | SUMITOMO CHEMICAL TAKEDA AGRO COMPANY, LIMITED (JP) | 2003-07-01 | — | — | US | disclosed |
| CN-1349381-A | Sulfonamide derivatives | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-05-15 | — | — | CN | disclosed |
| EP-1174028-A1 | SULFONAMIDE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2002-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10457707-B2 | Substituted urea depsipeptide analogs as activators of the CLPP endopeptidase | CLPP, DNPEP, PEPD | CYP11B1 4830/4885CYP11B2 4816/4885MAOA 2427/4885 |
| US-20040023938-A1 | Sulfonamide derivatives | FPR1, MRM1, SULT1E1 | CYP11B1 1371/4885CYP11B2 2030/4885MAOA 2405/4885 |
| US-20190048040-A1 | Substituted Urea Depsipeptide Analogs as Activators of the CLPP Endopeptidase | CLPP, DNPEP, PEPD | CYP11B1 4830/4885CYP11B2 4816/4885MAOA 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.